Clinical trial
Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in…
NCT00409409 · Stallergenes Greer, Industry · Completed
Key facts
| NCT number | NCT00409409 |
|---|---|
| Title | Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis |
| Official title | A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Paediatric Study of the Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Children Suffering From Grass Pollen Rhinoconjunctivitis |
| Lead sponsor | Stallergenes Greer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Allergy |
| Intervention type | Drug |
| Interventions | 300 IR grass pollen allergen extract tablet, Placebo tablet |
| Enrollment | 278 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Dec 8, 2006 |
| Last update posted | May 26, 2016 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: